Bausch Health Companies (TSE:BHC) Shares Down 2.3% – Time to Sell?

Posted by Alanna Baker on Jan 16th, 2026

Bausch Health Companies Inc. (TSE:BHC – Get Free Report) dropped 2.3% during trading on Thursday . The company traded as low as C$10.02 and last traded at C$10.11. Approximately 523,547 shares changed hands during trading, an increase of 16% from the average daily volume of 451,074 shares. The stock had previously closed at C$10.35.

Analysts Set New Price Targets

BHC has been the subject of several analyst reports. Raymond James Financial upgraded Bausch Health Companies to a “hold” rating in a research note on Monday, December 15th. Barclays raised shares of Bausch Health Companies to a “hold” rating in a research report on Monday, December 8th. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Bausch Health Companies presently has a consensus rating of “Hold”.

Read Our Latest Report on Bausch Health Companies

Bausch Health Companies Stock Performance

The stock has a market cap of C$3.75 billion, a price-to-earnings ratio of 10.42, a P/E/G ratio of 0.21 and a beta of 0.54. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94. The stock’s 50-day moving average is C$9.57 and its 200-day moving average is C$9.38.

Bausch Health Companies (TSE:BHC – Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The company reported C$0.48 earnings per share (EPS) for the quarter. Bausch Health Companies had a negative net margin of 1.88% and a positive return on equity of 15.87%. The company had revenue of C$2.68 billion during the quarter. On average, analysts expect that Bausch Health Companies Inc. will post 5.5472637 EPS for the current year.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.